Owing to their distinct self-renewal and differentiation properties,
human pluripotent stem cells (hPSCs), either human embryonic
stem cells (hESCs) or human induced pluripotent stem cells
(iPSCs), hold great potential as a cell source for regenerative medicine.
However, these properties also make them potentially
tumorigenicdeven a small number of undifferentiated hPSCs are
sufficient to generate teratomas when transplanted in vivo [1,2].
Hence, the risk of tumorigenesis is a major concern for the clinical
translation of all hPSC-derived products [3]. Animal studies documenting
the risk of teratoma formation following transplantation
of hPSC-derivatives have spurred efforts to evaluate and enhance